IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug,
certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women
with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant
(LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients
will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS
and repeatedly positive tests for LAC enrolled in a previous study by the investigators.
Phase:
Phase 2
Details
Lead Sponsor:
Ware Branch
Collaborators:
Hospital for Special Surgery, New York New York University School of Medicine NYU Langone Health University of Toronto